Jennifer A. Lockridge

2.2k total citations · 1 hit paper
12 papers, 1.7k citations indexed

About

Jennifer A. Lockridge is a scholar working on Molecular Biology, Epidemiology and Hematology. According to data from OpenAlex, Jennifer A. Lockridge has authored 12 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 4 papers in Epidemiology and 2 papers in Hematology. Recurrent topics in Jennifer A. Lockridge's work include RNA Interference and Gene Delivery (5 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Hepatitis B Virus Studies (3 papers). Jennifer A. Lockridge is often cited by papers focused on RNA Interference and Gene Delivery (5 papers), Advanced biosensing and bioanalysis techniques (4 papers) and Hepatitis B Virus Studies (3 papers). Jennifer A. Lockridge collaborates with scholars based in United States, Switzerland and United Kingdom. Jennifer A. Lockridge's co-authors include Shawn Zinnen, Keith Bowman, Kristi Jensen, Chandra Vargeese, Barry Polisky, Karin S. Blanchard, Dylan Morrissey, Susan F. Radka, Narendra K. Vaish and Vasant Jadhav and has published in prestigious journals such as Nature Biotechnology, PLoS ONE and Hepatology.

In The Last Decade

Jennifer A. Lockridge

12 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs

2005 908 citations Dylan Morrissey, Jennifer A. Lockridge et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jennifer A. Lockridge United States	10	1.5k	389	225	192	183	12	1.7k
Lars Aagaard Denmark	20	2.1k 1.4×	679 1.7×	374 1.7×	218 1.1×	120 0.7×	45	2.4k
Gisèle Degeest Belgium	10	2.1k 1.4×	807 2.1×	90 0.4×	338 1.8×	242 1.3×	11	2.6k
Dominique L. Ouellet Canada	16	1.1k 0.8×	578 1.5×	174 0.8×	133 0.7×	63 0.3×	22	1.4k
Nan Sook Lee United States	15	1.2k 0.8×	201 0.5×	334 1.5×	111 0.6×	141 0.8×	25	1.5k
Ashley M. Jacobi United States	17	1.5k 1.0×	173 0.4×	366 1.6×	164 0.9×	81 0.4×	25	1.9k
Tatiana Ketova United States	14	2.1k 1.4×	376 1.0×	291 1.3×	469 2.4×	79 0.4×	21	2.6k
Lingxun Duan United States	14	1.6k 1.1×	73 0.2×	271 1.2×	99 0.5×	104 0.6×	22	1.9k
Kusum Pandey United States	7	1.9k 1.3×	481 1.2×	1.1k 4.8×	154 0.8×	88 0.5×	8	2.3k
Ryan L. Setten United States	8	1.1k 0.7×	284 0.7×	105 0.5×	106 0.6×	28 0.2×	10	1.3k
James E. Hagstrom United States	22	2.4k 1.6×	283 0.7×	989 4.4×	203 1.1×	42 0.2×	31	2.7k

Countries citing papers authored by Jennifer A. Lockridge

Since Specialization

Citations

This map shows the geographic impact of Jennifer A. Lockridge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer A. Lockridge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer A. Lockridge more than expected).

Fields of papers citing papers by Jennifer A. Lockridge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer A. Lockridge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer A. Lockridge. The network helps show where Jennifer A. Lockridge may publish in the future.

Co-authorship network of co-authors of Jennifer A. Lockridge

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer A. Lockridge. A scholar is included among the top collaborators of Jennifer A. Lockridge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer A. Lockridge. Jennifer A. Lockridge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Roehl, Ingo, et al.. (2017). Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy. Molecular Therapy — Nucleic Acids. 8. 1–12. 34 indexed citations

Marlowe, Jennifer, et al.. (2017). Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics. Nucleic Acid Therapeutics. 27(4). 183–196. 21 indexed citations

Healey, Gareth D., Jennifer A. Lockridge, Shawn Zinnen, et al.. (2014). Development of Pre-Clinical Models for Evaluating the Therapeutic Potential of Candidate siRNA Targeting STAT6. PLoS ONE. 9(2). e90338–e90338. 6 indexed citations

Greenberg, Kenneth P., Edward S. Boyden, Jennifer A. Lockridge, et al.. (2011). Virally delivered Channelrhodopsin-2 Safely and Effectively Restores Visual Function in Multiple Mouse Models of Blindness. Molecular Therapy. 19(7). 1220–1229. 217 indexed citations

Kaiser, Peter K., R. C. Andrew Symons, Syed Mahmood Shah, et al.. (2010). RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027. American Journal of Ophthalmology. 150(1). 33–39.e2. 146 indexed citations

Healey, Gareth D., Shawn Zinnen, Jennifer A. Lockridge, et al.. (2010). Identification of small interfering RNA targeting Signal Transducer and Activator of Transcription 6: Characterisation and selection of candidates for pre-clinical development.. PubMed. 6(2). 401–10. 5 indexed citations

Beverly, Michael B., et al.. (2006). Liquid chromatography electrospray ionization mass spectrometry analysis of the ocular metabolites from a short interfering RNA duplex. Journal of Chromatography B. 835(1-2). 62–70. 42 indexed citations

Kobayashi, Hiroyuki, S. Gail Eckhardt, Jennifer A. Lockridge, et al.. (2005). Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56(4). 329–336. 28 indexed citations

Morrissey, Dylan, Jennifer A. Lockridge, Karin S. Blanchard, et al.. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnology. 23(8). 1002–1007. 908 indexed citations breakdown →

10.

Morrissey, Dylan, Karin S. Blanchard, Kristi Jensen, et al.. (2005). Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication†. Hepatology. 41(6). 1349–1356. 219 indexed citations

11.

Weng, David, Susan F. Radka, Ram Ganapathi, et al.. (2005). A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. Molecular Cancer Therapeutics. 4(6). 948–955. 52 indexed citations

12.

Brown‐Augsburger, Patricia, et al.. (2003). Development and validation of a sensitive, specific, and rapid hybridization-ELISA assay for determination of concentrations of a ribozyme in biological matrices. Journal of Pharmaceutical and Biomedical Analysis. 34(1). 129–139. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact